Literature DB >> 10739770

The gene for May-Hegglin anomaly localizes to a <1-Mb region on chromosome 22q12.3-13.1.

J A Martignetti1, K E Heath, J Harris, N Bizzaro, A Savoia, C L Balduini, R J Desnick.   

Abstract

The May-Hegglin anomaly (MHA) is an autosomal dominant platelet disorder of unknown etiology. It is characterized by thrombocytopenia, giant platelets, and leukocyte inclusion bodies, and affected heterozygotes are predisposed to bleeding episodes. The MHA gene has recently been localized, by means of linkage analysis, to a 13.6-cM region on chromosome 22, and the complete chromosome 22 sequence has been reported. We recently performed a genome scan for the MHA gene in 29 members of a large, multigenerational Italian family, and we now confirm that the MHA locus is on chromosome 22q12. 3-13.1. The maximal two-point LOD score of 4.50 was achieved with the use of marker D22S283, at a recombination fraction of.05. Haplotype analysis narrowed the MHA critical region to 6.6 cM between markers D22S683 and D22S1177. It is of note that the chromosome 22 sequence allowed all markers to be ordered correctly, identified all the candidate genes and predicted genes, and specifically determined the physical size of the MHA region to be 0. 7 Mb. These results significantly narrow the region in which the MHA gene is located, and they represent the first use of chromosome 22 data to positionally clone a disease gene.

Entities:  

Mesh:

Year:  2000        PMID: 10739770      PMCID: PMC1288213          DOI: 10.1086/302873

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  31 in total

1.  Mapping of a gene for May-Hegglin anomaly to chromosome 22q.

Authors:  S Kunishima; T Kojima; T Tanaka; T Kamiya; K Ozawa; Y Nakamura; H Saito
Journal:  Hum Genet       Date:  1999-11       Impact factor: 4.132

2.  The DNA sequence of human chromosome 22.

Authors:  I Dunham; N Shimizu; B A Roe; S Chissoe; A R Hunt; J E Collins; R Bruskiewich; D M Beare; M Clamp; L J Smink; R Ainscough; J P Almeida; A Babbage; C Bagguley; J Bailey; K Barlow; K N Bates; O Beasley; C P Bird; S Blakey; A M Bridgeman; D Buck; J Burgess; W D Burrill; K P O'Brien
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

3.  Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2.

Authors:  C Y Ho; B Otterud; R D Legare; T Varvil; R Saxena; D B DeHart; S E Kohler; J C Aster; S B Dowton; F P Li; M Leppert; D G Gilliland
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

4.  Fechtner syndrome--a variant of Alport's syndrome with leukocyte inclusions and macrothrombocytopenia.

Authors:  L C Peterson; K V Rao; J T Crosson; J G White
Journal:  Blood       Date:  1985-02       Impact factor: 22.113

5.  The inclusions of the May-Hegglin anomaly and Döhle bodies of infection: an ultrastructural comparison.

Authors:  J C Cawley; F G Hayhoe
Journal:  Br J Haematol       Date:  1972-04       Impact factor: 6.998

6.  The May-Hegglin anomaly: ultrastructure of the granulocytic inclusion.

Authors:  E H Jenis; A Takeuchi; D E Dillon; F B Ruymann; S Rivkin
Journal:  Am J Clin Pathol       Date:  1971-02       Impact factor: 2.493

7.  The May-Hegglin anomaly: platelet function, ultrastructure and chromosome studies.

Authors:  J M Lusher; J Schneider; I Mizukami; R K Evans
Journal:  Blood       Date:  1968-12       Impact factor: 22.113

8.  The May-Hegglin anomaly; a case report and chromosome studies.

Authors:  N Gausis; D W Fortune; M G Whiteside
Journal:  Br J Haematol       Date:  1969-06       Impact factor: 6.998

9.  Genetic linkage of autosomal-dominant Alport syndrome with leukocyte inclusions and macrothrombocytopenia (Fechtner syndrome) to chromosome 22q11-13.

Authors:  A Toren; N Amariglio; G Rozenfeld-Granot; A J Simon; F Brok-Simoni; E Pras; G Rechavi
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

10.  Defective neutrophil mobility in the May-Hegglin anomaly.

Authors:  J R Cabrera; G Fontán; F Lorente; C Regidor; M N Fernández
Journal:  Br J Haematol       Date:  1981-03       Impact factor: 6.998

View more
  3 in total

1.  Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.

Authors:  K E Heath; A Campos-Barros; A Toren; G Rozenfeld-Granot; L E Carlsson; J Savige; J C Denison; M C Gregory; J G White; D F Barker; A Greinacher; C J Epstein; M J Glucksman; J A Martignetti
Journal:  Am J Hum Genet       Date:  2001-10-04       Impact factor: 11.025

2.  Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria.

Authors:  C Solis; G I Aizencang; K H Astrin; D F Bishop; R J Desnick
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

3.  MYH-9 Related Platelet Disorders: Strategies for Management and Diagnosis.

Authors:  Karina Althaus; Andreas Greinacher
Journal:  Transfus Med Hemother       Date:  2010-09-15       Impact factor: 3.747

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.